Current issue #32, 2015

Roszdravnadzor builds up power

In early October, public discussion of amendments to the Code of Administrative Offences came to completion. The draft law provides for new types of offences and sanctions for medical and pharmaceutical professionals. Among other things, the document finally determines fines for physicians communicating with medreps, although they do not exceed 20,000 rubles. However, not all types of punishments are as insignificant as that. For some other violations, Roszdravnadzor (Federal Service for Surveillance in Healthcare and Social Development) plans to charge up to 5 million rubles or suspend the respective enterprise’s operations for 3 months.

[PharmVestnik # 31, 06/10/2015, p. 1, cont’d p.2]

From “white” to “grey”

Experts forecast that parallel imports may be permitted in 2017

A lot of pros and cons have been at stake in the debates regarding the implementation of parallel drug imports. However, experts are still uncertain about this phenomenon, the more so that the product importation mechanisms with certain “parallelism” properties have existed in Russia for a long time. A statement to this effect was made at the 7^th International Conference “What is Going On in the Pharmaceutical Market?”

[PharmVestnik # 31, 06/10/2015, p. 1, cont’d p.2]

The main thing is to get involved

It is wise to sign long-term contracts in crisis

A transfer to one-year budgeting has set many of pharmaceutical manufacturers on fire. Quite a lot of large companies are involved in the state bidding operations, and many of them have looked at long-term contracts as an option of collaborating with the state. But what kind of planning is it going to be if the government paces itself for just a year? However, some experts believe that it is worthwhile making long-terms contracts with the government. The main thing is to know how to do that. 

[PharmVestnik # 31, 06/10/2015, p. 1, cont’d p.3]

About drugs and oil

Day one of the 7^th International Conference “What is Going On in the Pharmaceutical Market?” was devoted to macroeconomic forecasts for the year 2016 as well as regulatory issues of the pharmaceutical industry. The agenda included the protracted transfer to the GMP standards as well as the extended VED (Vital and Essential Drugs) list and its effect on the market.

[PharmVestnik # 31, 06/10/2015, pp. 4-5]

Current regulatory framework may torpedo preferences under “odd-man-out” regulation

The pharmaceutical industry is waiting for the approval of the “odd-m...